
OPKO Health (OPK) Stock Forecast & Price Target
OPKO Health (OPK) Analyst Ratings
Bulls say
OPKO Health's recent strategic transaction is viewed favorably as it sharpens the company's focus on drug development while also enhancing its balance sheet. The company reported a Q4 2024 revenue of $183.6 million, reflecting a 0.9% year-over-year growth, which surpassed projections and indicates solid operational performance. Furthermore, management's commitment to improving BioReference's productivity and its aim for profitability by 2025, alongside a strengthened cash position and a realized gain from asset sales, collectively contribute to a positive financial outlook for the company.
Bears say
OPKO Health Inc reported a significant 17% year-over-year decline in diagnostics services revenue, totaling $103.1 million, primarily driven by reduced clinical test volumes linked to the sale of certain BioReference assets. For the full year of 2024, total revenue declined by 17% to $713.1 million, reflecting persistent challenges in both its diagnostics and pharmaceutical segments, with pharmaceutical products revenue decreasing by 13% to $37.4 million due to unfavorable foreign currency exchange rates. Additional risks that contribute to the negative outlook include potential lower-than-expected growth in diagnostics services, challenges in developing new pharmaceuticals, and fluctuations in sales due to competition and market dynamics.
This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.
OPKO Health (OPK) Analyst Forecast & Price Prediction
Start investing in OPKO Health (OPK)
Order type
Buy in
Order amount
Est. shares
0 shares